Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Aurora kinase A inhibitor

DRUG CLASS:

Aurora kinase A inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	MLN8237 Sensitive: C2 – Inclusion Criteria MLN8237 Sensitive : C2	MLN8237 Sensitive: C2 – Inclusion Criteria MLN8237 Sensitive : C2
KDM1A expression	Breast Cancer	KDM1A expression	Breast Cancer	MLN8237 Sensitive: C3 – Early Trials MLN8237 Sensitive : C3	MLN8237 Sensitive: C3 – Early Trials MLN8237 Sensitive : C3
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	MLN8237 Sensitive: C3 – Early Trials MLN8237 Sensitive : C3	MLN8237 Sensitive: C3 – Early Trials MLN8237 Sensitive : C3
CTNNB1 mutation	Lung Cancer	CTNNB1 mutation	Lung Cancer	VIC-1911 Sensitive: D – Preclinical VIC-1911 Sensitive : D	VIC-1911 Sensitive: D – Preclinical VIC-1911 Sensitive : D
TCF3-EPAS1 fusion	Acute Lymphocytic Leukemia	TCF3-EPAS1 fusion	Acute Lymphocytic Leukemia	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D
CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D
TP53 mutation	Small Cell Lung Cancer	TP53 mutation	Small Cell Lung Cancer	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D
TP53 mutation	Squamous Cell Carcinoma of Head and Neck	TP53 mutation	Squamous Cell Carcinoma of Head and Neck	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D
CDKN2A mutation	Non Small Cell Lung Cancer	CDKN2A mutation	Non Small Cell Lung Cancer	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D
AURKA overexpression	Esophageal Cancer	AURKA overexpression	Esophageal Cancer	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D
MYC overexpression	Thyroid Gland Carcinoma	MYC overexpression	Thyroid Gland Carcinoma	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D
CBFA2T3 - GLIS2 fusion	Acute Myelogenous Leukemia	CBFA2T3 - GLIS2 fusion	Acute Myelogenous Leukemia	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D
RB1 deletion	Mesothelioma	RB1 deletion	Mesothelioma	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	venetoclax + LY3295668 Sensitive: D – Preclinical venetoclax + LY3295668 Sensitive : D	venetoclax + LY3295668 Sensitive: D – Preclinical venetoclax + LY3295668 Sensitive : D
NTRK1 fusion	Colon Cancer	NTRK1 fusion	Colon Cancer	KRC-108 Sensitive: D – Preclinical KRC-108 Sensitive : D	KRC-108 Sensitive: D – Preclinical KRC-108 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + VIC-1911 Sensitive: D – Preclinical sotorasib + VIC-1911 Sensitive : D	sotorasib + VIC-1911 Sensitive: D – Preclinical sotorasib + VIC-1911 Sensitive : D
HMGA2 overexpression	Prostate Cancer	HMGA2 overexpression	Prostate Cancer	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D	MLN8237 Sensitive: D – Preclinical MLN8237 Sensitive : D